The company will innovate within decentralized healthcare capabilities to conduct efficient and relevant research. Credit: Max Acronym/Shutterstock.
The Biomedical Advanced Research and Development Authority (BARDA) has selected Allucent as part of a five-year agreement in the U.S. for its new Decentralized Clinical Operations for Healthcare and Research (D-COHRe) initiative.
The initiative aims to support the development of medical countermeasures and improve preparedness for public health emergencies.
Under the D-COHRe initiative, Allucent will expand its decentralized clinical research capabilities, leveraging advances in healthcare to build sustainable capacity and evaluate medical countermeasures in real-world settings.
The emphasis will be on conducting hybrid and fully decentralized studies, and on using home care, telecare, mobile care and alternative study locations.
Allucent supports these studies with secure data collection technology, participant engagement tools, and research services to ensure participant enrollment and retention.
During the five-year programme, the company will innovate within decentralised healthcare capabilities to conduct efficient and relevant research.
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive edge.
View profiles in the store
Company Profile – Free Sample
Your download email will arrive shortly
We are convinced of the unique quality of our company profiles. However, we want you to make the most beneficial decision for your company, so we offer a free sample that you can download by submitting the form below
By GlobalData
Country * United KingdomUSAfghanistanAland IslandsAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaSouth PoleAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and Herzegovina
BotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral-African Republic
ChadChiliChinaChristmas IslandCocos IslandsColombiaComorosCongoDemocratic Republic of CongoCook IslandsCosta RicaIvory CoastCroatiaCubaCuracaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuyanaFrench PolynesiaFrench Southern Territories
GabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard and McDonald Islands
Holy SeeHondurasHong-KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiNorth KoreaSouth KoreaKuwaitKyrgyzstanLaoLatviaLebanonLesothoLiberiaLibya
LiechtensteinLithuaniaLuxembourgMacau
Macedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldaviaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueBurmaNamibiaNauruNepalThe NetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk Islandnorthern Mariana Islands
NorwayOmanPakistanPalauPalestinian territoryPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarMeetingRomaniaRussian FederationRwandaSaint Helena, Assumption and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint-Pierre and Miquelon
Saint Vincent and the Grenadines
SamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSpainSri LankaSudanSurinameSpitsbergen and Jan Mayen
SwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzaniaThailandEast TimorTo goTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos Islands
TuvaluUgandaUkraineUnited Arab EmiratesMinor Outlying Islands of the United States
UruguayUzbekistanVanuatuVenezuelaVietnamBritish Virginislands
American virgin islandsWallis and FutunaWestern SaharaYemenZambiaZimbabweKosovo
Industry *Academy & EducationAerospace, Defence and SecurityAgricultureAsset managementAutomotiveBanking & PaymentsChemicalsBuildCustomerFood ServiceGovernment, industry associations and NGOsHealth and fitnessHospitals & Healthcare
HR, recruitment and personnel placementInsuranceInvestment bankingLegal servicesManagement adviceMarketing advertising
Media & PublishingMedical devicesMiningOil gasPackagingPharmaceuticalsEnergy & UtilitiesPrivate equityPropertyRetailSportTechnologyTelecommunicationsTransport & LogisticsTravel, Tourism & HospitalityVenture capital
Click here to opt out of receiving curated news, reports and event updates from Clinical Trials Arena.
Send and download
Please visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information about your rights in relation to your personal data and how to opt-out of future marketing communications. Our services are intended for business subscribers and you warrant that the email address provided is your business email address.
The company will also identify challenges in implementing decentralized trials and monitor the success and sustainability of the model.
Funding for this project is provided by the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response.
Mark Goldberg, Chairman and CEO of Allucent, said: “In the wake of the Covid-19 pandemic, there is an urgent need and unprecedented opportunity to realize the potential of decentralized clinical trials.
“Allucent is proud to partner with BARDA on this important initiative to strengthen pandemic preparedness by advancing decentralized clinical trial capabilities. We look forward to applying our expertise in decentralized trials to validate, test, and deploy novel products, technologies, and approaches intended for decentralized use with the agility needed during a public health emergency.”
In May 2024, Allucent received a $25.5 million grant from the Biomedical Advanced Research and Development Authority (BARDA) to support a decentralized clinical trial of a Covid-19 vaccine.
Sign up for our daily news digest!
